Neuberger Berman Group LLC trimmed its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 0.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,827,773 shares of the biopharmaceutical company’s stock after selling 17,064 shares during the period. Neuberger Berman Group LLC owned about 0.23% of Celgene Corporation worth $237,373,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation during the first quarter valued at approximately $118,000. Acropolis Investment Management LLC acquired a new position in Celgene Corporation during the second quarter valued at approximately $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares in the last quarter. Rational Advisors LLC acquired a new position in Celgene Corporation during the second quarter valued at approximately $156,000. Finally, Oakworth Capital Inc. lifted its position in Celgene Corporation by 11.7% during the second quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 127 shares in the last quarter. 79.39% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Celgene Corporation (CELG) opened at 100.97 on Wednesday. The firm has a market cap of $78.99 billion, a P/E ratio of 31.27 and a beta of 1.88. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a 50-day moving average of $134.67 and a 200 day moving average of $129.65.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.58 earnings per share. Equities analysts predict that Celgene Corporation will post $7.33 EPS for the current year.
In other news, Director Ernest Mario sold 18,506 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares in the company, valued at $9,061,220.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the sale, the director now owns 9,250 shares in the company, valued at approximately $1,286,027.50. The disclosure for this sale can be found here. Insiders have sold 38,733 shares of company stock worth $5,259,359 in the last 90 days. Company insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Neuberger Berman Group LLC Sells 17,064 Shares of Celgene Corporation (CELG)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/01/neuberger-berman-group-llc-sells-17064-shares-of-celgene-corporation-celg.html.
A number of brokerages have weighed in on CELG. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $175.00 price target (up from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 27th. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research note on Friday, October 20th. BMO Capital Markets reiterated an “outperform” rating and set a $160.00 price objective (up previously from $152.00) on shares of Celgene Corporation in a research note on Friday, July 28th. Finally, Leerink Swann reiterated a “buy” rating and set a $156.00 price objective on shares of Celgene Corporation in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the stock. Celgene Corporation has a consensus rating of “Buy” and an average target price of $139.64.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.